Global Hunter Securities Starts Vical (VICL) at Buy; The Pieces Have Come Together to Carry Positive Momentum Into '12
Tweet
Share
E-mailGet Alerts VICL Hot Sheet
Price: $0.68 --0%
Rating Summary:
3 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Global Hunter Securities initiates coverage on Vical (NASDAQ: VICL) with a Buy. PT $9.00.
Global analyst says, "With the announcement of partnering TransVax development in hematopoietic stem cell transplantation with Astellas, Vical made tremendous progress advancing its clinical programs in 2011. Allovectin continues to be the key value driver, which we anticipate will position the company with the leading melanoma therapy and a blockbuster opportunity in the 2013 timeframe. We anticipate the company will further monetize its proprietary adjuvant, Vaxfectin, which has shown versatility and potential for use in enhancing the ability of vaccines to harness the immune response against multiple pathogens. With the HSV-2 vaccine also poised for high value partnering, Vical’s clinical programs have strong momentum going into 2012."
For an analyst ratings summary and ratings history on Vical click here. For more ratings news on Vical click here.
Shares of Vical closed at $4.41 yesterday.
Global analyst says, "With the announcement of partnering TransVax development in hematopoietic stem cell transplantation with Astellas, Vical made tremendous progress advancing its clinical programs in 2011. Allovectin continues to be the key value driver, which we anticipate will position the company with the leading melanoma therapy and a blockbuster opportunity in the 2013 timeframe. We anticipate the company will further monetize its proprietary adjuvant, Vaxfectin, which has shown versatility and potential for use in enhancing the ability of vaccines to harness the immune response against multiple pathogens. With the HSV-2 vaccine also poised for high value partnering, Vical’s clinical programs have strong momentum going into 2012."
For an analyst ratings summary and ratings history on Vical click here. For more ratings news on Vical click here.
Shares of Vical closed at $4.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy
- Lake Street Starts RF Industries Ltd. (RFIL) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
